Insider Selling: Personalis (NASDAQ:PSNL) CFO Sells 51,251 Shares

Personalis, Inc. (NASDAQ:PSNL) CFO Aaron Tachibana sold 51,251 shares of the stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $13.18, for a total transaction of $675,488.18. Following the completion of the transaction, the chief financial officer directly owned 198,833 shares of the company’s stock, valued at approximately $2,620,618.94. The trade was a 20.49% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Aaron Tachibana also recently made the following trade(s):

• On Thursday, June 4th, Aaron Tachibana sold 40,000 shares of Personalis stock. The stock was sold at an average price of $12.01, for a total value of $480,400.00.
• On Friday, May 29th, Aaron Tachibana sold 38,799 shares of Personalis stock. The stock was sold at an average price of $11.58, for a total value of $449,292.42.

Personalis Stock Up 3.4%

NASDAQ PSNL traded up $0.43 during trading hours on Friday, hitting $13.02. 8,354,545 shares of the company were exchanged, compared to its average volume of 3,223,766. Personalis, Inc. has a 52 week low of $3.84 and a 52 week high of $13.37. The stock has a 50-day moving average price of $8.42 and a 200 day moving average price of $8.29. The stock has a market cap of $1.36 billion, a PE ratio of -12.76 and a beta of 2.28.

Personalis (NASDAQ:PSNL) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.06). The company had revenue of $15.47 million during the quarter, compared to the consensus estimate of $14.48 million. Personalis had a negative net margin of 148.11% and a negative return on equity of 43.52%. As a group, sell-side analysts anticipate that Personalis, Inc. will post -1.06 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in PSNL. Royal Bank of Canada increased its stake in Personalis by 3.2% in the 1st quarter. Royal Bank of Canada now owns 78,341 shares of the company’s stock worth $275,000 after buying an additional 2,395 shares during the period. Dynamic Technology Lab Private Ltd boosted its position in Personalis by 75.6% in the 1st quarter. Dynamic Technology Lab Private Ltd now owns 76,729 shares of the company’s stock valued at $269,000 after buying an additional 33,044 shares during the period. Goldman Sachs Group Inc. grew its stake in Personalis by 55.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 284,426 shares of the company’s stock worth $998,000 after acquiring an additional 101,706 shares in the last quarter. Focus Partners Wealth purchased a new position in shares of Personalis during the first quarter worth approximately $47,000. Finally, JPMorgan Chase & Co. increased its position in shares of Personalis by 505.6% during the second quarter. JPMorgan Chase & Co. now owns 29,491 shares of the company’s stock worth $193,000 after acquiring an additional 24,621 shares during the period. 61.91% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on PSNL shares. Weiss Ratings restated a “sell (d-)” rating on shares of Personalis in a report on Tuesday, April 21st. BTIG Research cut their price target on shares of Personalis from $13.00 to $11.00 and set a “buy” rating on the stock in a report on Monday, May 11th. Wall Street Zen lowered shares of Personalis from a “hold” rating to a “sell” rating in a research report on Saturday, June 13th. Needham & Company LLC boosted their target price on Personalis from $10.00 to $12.00 and gave the company a “buy” rating in a research report on Friday, February 27th. Finally, Morgan Stanley cut their target price on Personalis from $10.00 to $9.00 and set an “equal weight” rating on the stock in a research note on Tuesday, May 12th. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $11.00.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.